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Size-Dependent Pulmonary Impact of Thin Graphene Oxide
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Safety assessment of graphene-based materials (GBMs) including graphene
oxide (GO) is essential for their safe use across many sectors of society. In
particular, the link between specific material properties and biological effects
needs to be further elucidated. Here, the effects of lateral dimensions of GO
sheets in acute and chronic pulmonary responses after single intranasal
instillation in mice are compared. Micrometer-sized GO induces stronger
pulmonary inflammation than nanometer-sized GO, despite reduced
translocation to the lungs. Genome-wide RNA sequencing also reveals
distinct size-dependent effects of GO, in agreement with the histopathological
results. Although large GO, but not the smallest GO, triggers the formation of
granulomas that persists for up to 90 days, no pulmonary fibrosis is observed.
These latter results can be partly explained by Raman imaging, which
evidences the progressive biotransformation of GO into less graphitic
structures. The findings demonstrate that lateral dimensions play a
fundamental role in the pulmonary response to GO, and suggest that airborne
exposure to micrometer-sized GO should be avoided in the production plant
or applications, where aerosolized dispersions are likely to occur. These
results are important toward the implementation of a safer-by-design
approach for GBM products and applications, for the benefit of workers and
end-users.
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Graphene and other two dimensional
(2D) materials have generated substantial
commercial interest due to their unique
combination of physicochemical proper-
ties that are attractive for a wide range of
applications.[1,2] Several methods of large-
scale production have been developed since
the first isolation of graphene, yielding a
range of different forms of graphene-based
materials (GBMs) whose properties such
as lateral dimensions, thickness, and sur-
face chemistry can vary significantly.[3,4]
In particular, the low production cost of
graphene oxide (GO) has contributed to
the emergence of various commercial
products based on GO-based composites,
dispersions, or spray coatings.[5] As a result
of this sustained commercial expansion,
it is expected that exposure to GBMs via
inhalation of aerosolized materials will
increase, raising concerns about the po-
tential impact of inhaled GBMs on human
health.[6,7]
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In respect to the pulmonary route of exposure, graphene
nanoplatelets (GNPs) have been the most widely studied GBMs
to date, with several reports of transient inflammation after pul-
monary exposure.[8–14] In addition, Roberts et al. demonstrated
that GNPs with large lateral dimensions (5–20 µm) have a more
detrimental impact on the lungs than their smaller counterparts
(<2 µm) following oropharyngeal aspiration,[15] supporting the
view that dimensions of these materials are a major determinant
of their pulmonary toxicity. However, despite evidence that GNPs
may persist in the lungs without being inflammogenic even after
6 weeks,[16] longer term consequences of material persistence in
the alveolar region, such as late onset disease or carcinogenesis,
remain largely unknown.
In contrast, pulmonary responses to GO have not been stud-
ied to the same extent. Despite numerous in vitro studies on
the toxicity of GO, there is not yet a consensus regarding the
key properties underlying these effects due to the considerable
variability in the physicochemical properties of the tested mate-
rials, as well as the use of different cell models.[7] Indeed, while
studies of the impact of GO on macrophage cell lines have sug-
gested toxicity,[17] we have recently reported that single to few-
layer GO is non-cytotoxic for primary human macrophages (at
the doses tested).[18] On the other hand, endotoxin-free GO sheets
displayed cytotoxicity toward primary human neutrophils, result-
ing in the formation of so-called extracellular traps.[19] Further-
more, using a lung epithelial cell line, we demonstrated that large
GO sheets (5–15 µm) elicited stronger cytotoxic responses com-
pared to small GO sheets (50–200 nm).[20] Similarly, Ma et al.
reported enhanced inflammatory responses in the lungs of an-
imals exposed to large GO sheets (750–1300 nm) when com-
pared to small GO (50–350 nm).[21] However, only the acute in-
flammatory response was assessed in the latter study, and ques-
tions regarding the potential long-term effects of GO remain to be
addressed.
With this in mind, the aim of the present study was to inves-
tigate whether lateral dimensions play a significant role in the
pulmonary response to GO at short- and long-term after single
exposure in mice. Considering the literature, we hypothesized
that micrometer-sized GO sheets would induce a more deleteri-
ous pulmonary response than nanometer-sized GO after single
intranasal (i.n.) instillation (50 µg per mouse). To this end, we in-
vestigated both acute and chronic responses to three different GO
materials produced with distinct lateral dimensions,[22] for up to
90 days after single exposure. Pulmonary responses were char-
acterized in terms of conventional histopathological markers, re-
cruitment of immune cells, and secretion of inflammatory cy-
tokines. Furthermore, we applied genome-wide RNA sequencing
(RNA-seq)[23] in order to evaluate potential differences between
the three GO materials at the level of gene expression. However,
the probability of inducing such effects could be reduced by a
lower deposited dose of larger GO sheets in the alveolar region
compared to smaller ones, as a result of greater clearance from
the upper respiratory tract following intranasal administration.
To test this possibility, we investigated the biodistribution and
biodegradation of GO using a combination of inductively coupled
plasma mass spectrometry (ICP-MS) and Raman spectroscopy,
and then contrasted the inflammatory effects of the three GO
materials with their biokinetics (i.e., distribution, biotransforma-
tion, and/or clearance from the lungs). Under the tested con-
ditions, we found that the largest GO sheets were causing the
most adverse, widespread, and long-term effects in mice, despite
a lower lung deposition, but in agreement with persistent gran-
ulomas, while the pulmonary response to the smallest GO was
predominantly acute and transient, in line with a faster clearance
from the lungs.
2. Results
2.1. Characteristics of GO Sheets and Benchmark Materials
The three GO materials used in the present study were pro-
duced under endotoxin-free conditions,[22] and yielded single to
few-layer sheets with similar surface chemistry and thickness,
but with varying lateral dimensions (full characterization was
previously reported in ref. [22] indicative values in Table S1,
Supporting Information). Large GO (l-GO) was comprised of
micrometer-sized sheets ranging between 1 and 30 µm in lat-
eral dimensions, whereas small GO (s-GO) was made of sheets
between 50 nm and up to 2 µm. The third materials, so-called
ultra-small GO (us-GO) sheets were all smaller than 300 nm, and
no micrometer-sized sheets were observed in these samples. Fi-
nally, multi-walled carbon nanotubes (MWCNT; Mitsui-7), classi-
fied by the International Agency for Research on Cancer (IARC)
as a potential human carcinogen on the basis of numerous ani-
mal studies,[24,25] was included as a benchmark material, known
to induce chronic inflammation and fibrosis. Notably, these nan-
otubes have lengths comparable to the lateral dimensions of the
l-GO tested here, ranging from 1 to 20 µm (median = 3.86 µm),
and a high aspect ratio, with an average width of 49 ± 13.4 nm.[24]
2.2. Biodistribution of GO Sheets After Intranasal
Instillation in Mice
In order to estimate the lung burden induced by GO after i.n.
instillation (50 µg per mouse), we functionalized GO with NH2-
PEG4-DOTA (GO-DOTA) as previously reported
[26] and chelated
the GO-DOTA complexes with metal isotopes (111In or 115In). Iso-
tope labelling purity and stability in physiological media were
tested using 111In (Figure S1, Supporting Information), which
demonstrated the suitability of these probes for biodistribu-
tion studies. Qualitative estimation of biodistribution using au-
toradiography of lungs exposed to 50 µg GO-DOTA[111In] com-
plexes revealed different intensities (Figure 1A), suggesting a
size-dependent translocation to the lower respiratory tract 1 day
after i.n. instillation. While l-GO translocated less than the other
two GO materials, s-GO seemed to translocate more effectively
to the lungs compared to us-GO. For quantitative biodistribu-
tion (up to 7 days after instillation), we use ICP-MS after chelat-
ing the natural isotope 115In to the GO-DOTA complexes (Fig-
ure 1B). We again observed a size-dependent deposition in the
lower respiratory tract (reported in the panel as lungs and tra-
chea; Figure 1C), with l-GO corresponding to the lowest de-
posited dose (7.01% ± 4.42%) and s-GO sheets to the highest
(17.48% ± 7.44%). At an intermediate level, 12.08% (± 5.77%)
of instilled us-GO sheets reached the lower respiratory tract (Ta-
ble S2, Supporting Information), and persisted in both lungs
and trachea up to the latest time point tested here (7 days post
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Figure 1. GO sheets translocate to the lower respiratory tract after intranasal instillation. Mice were instilled with DOTA-functionalized GO sheets labeled
with 115In (natural) or 111In (radioactive), and the organs were collected 1 and 7 days after exposure. A) Autoradiography of lungs dissected from mice
instilled with GO-DOTA[111In] 1 day after exposure. B) Heatmap illustrates tissue distribution and persistence of GO-DOTA[115In] in the respiratory tract
compared to DOTA[115In] control, at days 1 and 7 after i.n. instillation. Each block represents the mean amount of GO in the respective organ, quantified
by ICP-MS, which was normalized as % instilled dose (ID) per gram of dry tissue. C) Quantification of 115In by ICP-MS in the lungs and trachea from
mice exposed to GO-DOTA[115In] or the DOTA[115In] control reveals size-dependent distribution of GO in the respiratory tract. Individual data points
corresponding to each animal are plotted alongside mean ± SD (n = 4). Data were analyzed using a two-way ANOVA test with post hoc Sidak’s multiple
comparisons test. Significant differences between treatments are plotted with (*), whereas differences over time are plotted with (#). In both cases,
statistical significance is reported as: (*), p < 0.05; (**), p < 0.01; (***), p < 0.001; (****), p < 0.0001. Remaining organs are plotted in Figure S2,
Supporting Information.
exposure). After normalizing by the lung dry weight, the uptake
of GO sheets by the lungs was calculated to be 11.88 ± 6.38 mg
g−1 for l-GO, 30.72 ± 13.55 mg g−1 for s-GO, and 20.92 ± 6.37 mg
g−1 for us-GO (Table S3, Supporting Information). Lung uptake
of s-GO and us-GO was significantly greater than that of the
DOTA control (p < 0.0001 for s-GO and p = 0.0102 for us-GO),
which totaled 4.63 ± 2.52 mg g−1. Although the delivered dose
to the lungs and trachea was lower than s-GO and us-GO, l-GO
was found to be persistent in the trachea, with a detected dose
that was about 6.6 times greater than DOTA at day 7 post in-
stillation (p = 0.0450). Similar retention was also observed for
us-GO, with detected doses in the lungs and trachea that were
21 (p = 0.0045) and 5.2 times (p = 0.0003) greater than DOTA,
respectively. On the other hand, the amount of s-GO in the
lungs and trachea decreased by 73% (p = 0.0002) and 66% (p =
0.0191), respectively, between day 1 and 7, suggesting a greater
clearance.
The lower amount of l-GO found in the lower respiratory tract
correlated with its greater detection in extra-pulmonary organs
such as the nasal cavity (p < 0.0037 compared to all other treat-
ments) or the gastrointestinal (GI) tract (p= 0.0008 versus DOTA)
at day 1 post exposure (Figure S2, Supporting Information). Sig-
nificant translocation to the gastrointestinal tract was also ob-
served for s-GO (p = 0.0427) compared to DOTA. Moreover, the
amount of s-GO in the kidney was 4.9 and 3.6 times greater than
DOTA (p = 0.0159) and l-GO (p = 0.0315), respectively. These
results suggested the translocation of s-GO to the bloodstream,
with subsequent urinary excretion following glomerular filtra-
tion, in line with previous observations following other admin-
istration routes.[26,27] However, this translocation was not accom-
panied by a significant retention in organs of the reticuloendothe-
lial system such as liver or spleen, compared to the DOTA control
(p = 0.5014). The continuing decrease in signal from the nasal
cavity after l-GO exposure suggested that these materials were
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efficiently eliminated via mucociliary clearance. On the other
hand, us-GO translocated significantly from the nasal cavity to
the brain over time (p = 0.0005), with a retained dose at day 7
post instillation that was at least 8 times higher than the other
treatments (p < 0.0002), most likely because of the smaller di-
mensions of us-GO. No significant accumulation in the remain-
ing extra-pulmonary organs was observed for any material com-
pared to the DOTA control. These results suggested that lateral
dimensions affect the pulmonary deposition of GO sheets and
their biokinetics, which may ultimately determine their biologi-
cal impact. Because the amount of GO reaching the lungs was
randomly distributed in each lobe (Figure S2, Supporting Infor-
mation), we decided for each animal to sample each lobe and then
pool these samples in order to further characterize the overall pul-
monary response (see details below).
2.3. Tissue Response to GO Sheets after Intranasal Instillation
Pulmonary responses to GO sheets were assessed at days 1,
7, 28, and 90 after exposure (Figure 2; Figure S3, Supporting
Information). Lung histopathology indicated an acute inflam-
matory response at days 1 and 7 post instillation, which was
characterized by alveolar wall thickening with infiltration of pre-
dominantly mononuclear cells in the interstitium for all three
GO materials. Chronic inflammation was evidenced by the devel-
opment of non-necrotizing peri-bronchiolar granulomas in the
lungs of mice exposed to s-GO and l-GO at days 28 and 90 post
exposure (Figure 2A). These granulomas were localized only in
areas with significant agglomeration of GO. Moreover, the size of
these granulomas correlated with the lateral dimensions of the
administered materials (the larger the GO sheets, the bigger the
granulomas). Quantification of areas showing interstitial infiltra-
tion revealed a size-dependent effect of GO materials, with l-GO
inducing the most significant pulmonary infiltration at days 28 (p
= 0.0218) and 90 (p = 0.0002) compared to the negative control
(Figure S3, Supporting Information). Similarly, s-GO also trig-
gered a significant granulomatous response 28 days after instilla-
tion (p= 0.0203). However, this was followed by a reduction of the
infiltrated areas after 90 days (p = 0.0187). In contrast, us-GO did
not induce a significant granulomatous response in the lungs,
with the parenchyma recovering completely from acute intersti-
tial inflammation at day 28 post instillation, and showing similar
histological features to mice treated with the negative (vehicle)
control. As expected on the basis of previous reports, MWCNTs
(MWCNT-7), used here as positive control, induced both acute
and chronic interstitial infiltration (Figure S3, Supporting Infor-
mation), showing inflammatory patterns similar to or worse than
l-GO at 28 days after exposure (p < 0.0293). Noticeably, chronic
persistent inflammation in response to MWCNTs only occurred
in areas of material agglomeration in a similar fashion as for l-
GO and s-GO.Because chronic histopathological inflammation coincided
with the apparent persistence of GO, as evidenced by the pres-
ence of dark brown matter at 90 days post exposure, we also as-
sessed whether lung fibrosis was associated to granulomas at the
two latest time points. To this end, Masson’s trichrome stain-
ing was used to reveal the deposition of collagen (Figure 2B).
As expected, MWCNTs promoted interstitial fibrosis in the alveo-
lar region, already by day 7 (Figure S3, Supporting Information),
which coincided with areas of granulomatous inflammation. In
agreement with this data, exposure to MWCNTs also increased
the expression of the known fibrosis marker TGF-𝛽 by 96% (p =
0.0453) compared to the vehicle control (Figure 2C). On the other
hand, none of the three GO materials induced any obvious colla-
gen deposition or upregulation of TGF-𝛽 compared to control, in
spite of the formation of persistent granulomas after exposure to
l-GO or s-GO.
2.4. Evidence of Biotransformation of GO Sheets in the Lungs
Lack of fibrosis despite the persistence of GO materials in the
lungs could be attributed to the ability of the host tissue to
transform the foreign material into a less reactive material.[28]
To evaluate this possibility, we performed Raman mapping of
lung sections from exposed animals (Figure 3). The presence
of GO in the lungs produced a specific Raman signature (Fig-
ure S4, Supporting Information), whose evolution over time can
be used as an indicator of biotransformation resulting from the
loss of the crystalline structure of the material. We therefore an-
alyzed the Raman “fingerprints” of GO in the lungs by Raman
spectroscopy-based imaging (Figure 3). At day 1, whilst l-GO was
predominantly identified as large agglomerates associated with
the lung parenchyma, s-GO and us-GO were found in the air-
ways, mainly within circular features resembling individual cells
(Figure 3A). In agreement with the results obtained from ICP-
MS (Figure 1C) and autoradiography (Figure 1A) experiments, a
more widespread and persistent (up to 7 days) signal could be
observed over time for us-GO compared to s-GO, suggesting a
slower clearance of the former compared to the latter material.
Interestingly, all three GO materials could still be detected up
to 28 days after administration, though the Raman signal cor-
responding to the starting materials was dampened from day 1
to 28, suggesting that the structure of the materials was differ-
ent from the starting materials. Besides the indication of clear-
ance, the decreased Raman signal intensities over time suggested
that all three GO materials underwent biotransformation[29] (Fig-
ure 3B; Figures S5–S7, Supporting Information). Fine spectral
analysis revealed that all GO materials exhibited time depen-
dent spectroscopic changes. Despite the apparent increase from
1.32 ± 0.09 to 1.38 ± 0.18, us-GO did not display significant
changes in level of crystalline disorder, revealed by the ratio be-
tween the D and G bands (ID/IG).
[30] Nevertheless, this material
suffered the most dramatic reduction in Raman signal intensity,
which suggested that either us-GO sheets were cleared from the
lungs or biotransformation was leading to their disappearance
via biodegradation. Additional spectroscopic features indicative
of biotransformation were noted, such as the dislocation of the
G band from 1594 to 1603 cm−1 at day 28 post exposure (p =
0.0211) suggesting the emergence of a D’ band that is merged
to the G band. On the other hand, s-GO was the least affected
material since no spectroscopic features changed significantly
over time, including a constant ID/IG ratio at 1.35 ± 0.12 after
28 days. Interestingly, l-GO revealed the most significant spectro-
scopic changes, as evidenced by Raman analysis, including a de-
crease in ID/IG band from 1.48± 0.07 to 1.38± 0.08 at day 28 post
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Figure 2. Pulmonary exposure to GO induces size-dependent granulomatous inflammation in the lungs. Lung sections from mice instilled with GO
were extracted at 1, 7, 28, and 90 days after i.n. instillation. A) Representative images of sections stained with H&E and Masson’s trichrome at days
28 and 90 were acquired using a 20x magnification. Remaining time points are shown in Figure S4, Supporting Information. Arrows indicate areas of
significant immune cell infiltration in response to the presence of GO, with alveolar wall thickening and granuloma formation. Scale bars = 100 µm.
B) Despite granuloma formation, l-GO failed to induce significant collagen deposition, a typically hallmark for pulmonary fibrosis. Images correspond
to areas highlighted with a yellow box in the l-GO group (MWCNT group is presented in Figure S4, Supporting Information). Scale bars = 50 µm. C)
Small portions of each individual lobe were dissected for RNA extraction and RT-qPCR. Gene expression of TGF-𝛽 was quantified as relative fold increase
compared to the negative control (Dextrose) at each time point. Data are presented as individual points corresponding to each animal, alongside mean
values ± SD are presented (n = 4–5). Statistical analysis was performed using a Kruskal–Wallis test with post hoc Dunn’s multiple comparisons test
against the negative control: (*), p < 0.05. The temporal variation of TGF-𝛽 expression in the lungs was also analyzed using a Kruskal–Wallis test with
post hoc Dunn’s multiple comparisons test: (#), p < 0.05.
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Figure 3. GO sheets undergo biodegradation and/or clearance from the lungs after pulmonary exposure. Lung cryosections were obtained from mice
exposed to l-GO, s-GO, and us-GO. A) Raman maps are plotted overlaying bright-field images, with the intensity scale referring to the correlation between
the acquired spectrum for each pixel of the map and the reference spectrum of GO presented in Figure S4, Supporting Information. Presence of s-GO and
us-GO is emphasized in inset figures, corresponding to areas highlighted in yellow. Scale bars= 100 µm. B) Representative Raman spectra corresponding
to the average spectrum at each time point evidence biotransformation of GO in the lungs, with decreased signal intensity and spectroscopic changes
including the shifted position of the G band and the variation in the relative intensity of the D band.
instillation (p = 0.0332) and the dislocation of the G band from
1594 to 1602 cm−1 (p = 0.0181). This material presented a higher
ID/IG band at day 1 post exposure compared to s-GO and us-GO,
despite their similar structure before administration.[22] Follow-
ing this initial increase, a decreased ID/IG ratio at day 28 sug-
gested that l-GO had become more amorphous than the other two
materials, with defects becoming more widespread with time,
thus reducing the sp2 conjugated areas (i.e., loss of crystalline
structure).[30]
2.5. Inflammatory Response to GO Sheets in the Airways and
Lungs
Intranasal instillation with GO dispersions (50 µg per mouse) did
not result in acute toxicity, although mice instilled with s-GO and
us-GO suffered mild weight loss, in line with higher lung bur-
den, followed by full recovery within 4 days post exposure (Fig-
ure S8A, Supporting Information). Acute pulmonary responses
were assessed by measuring total protein and lactate dehydroge-
nase (LDH) release to the airways. The analysis of bronchoalve-
olar lavage (BAL) fluid revealed size-dependent disruption of the
air-blood barrier, as suggested by the release of proteins to the air-
ways (Figure S8B, Supporting Information). Nevertheless, no sta-
tistical significance was observed compared to the negative con-
trol, and only MWCNTs inducing 2.7 times more protein exuda-
tion 7 days after instillation (p = 0.0325). Exposure to any of the
three GO materials was followed by rapid recovery after 7 days,
which was maintained for up to 28 days. Cytotoxicity levels of
s-GO at 7 days after administration were 2.4-fold greater than ve-
hicle control (p = 0.0034), suggesting that the biological response
to GO may develop over time (Figure S8C, Supporting Informa-
tion), in a similar fashion to the observed granuloma formation
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Figure 4. GO sheets trigger acute recruitment of interstitial macrophages after pulmonary exposure. Lungs of mice exposed to carbon nanomaterials
were dissected 1 and 7 days after i.n. instillation, and digested in order to extract cells for flow cytometry. A) Heatmap showing the variation in abundance
of immune cell populations relatively to the negative control (Dextrose). Each block represents the mean value, after normalization to the average total
number of cells in a specific immune cell population (n = 4). Absolute cell counts for each immune cell population corresponded to the product of the
relative abundance in percentage of live CD45+ cells and the total number of live cells determined by Trypan Blue assay. B) Representative images showing
the relative abundance of myeloid cells (CD11b+CD11c−) 1 day after exposure to carbon nanomaterials (see Figure S10, Supporting Information for
gating strategy). Exposure to l-GO and MWCNT increased the relative amount of interstitial macrophages (CD64+), in contrast to a decreased population
of patrolling monocytes (CD64−Ly6C−), thus evidencing an acute inflammatory response.
(Figure 2). MWCNTs did not induce significant acute effects, de-
spite a mild increase in cytotoxicity 1 day after administration
(p = 0.0511).
Acute responses were further evaluated by quantifying the re-
cruitment of leukocytes in the airways by differential staining of
the cells recovered from bronchoalveolar lavage at days 1, 7, and
28 post exposure (Figure S9, Supporting Information). All three
GO materials induced significant recruitment of polymorphonu-
clear cells (PMN), with s-GO eliciting the most acute effects com-
pared to the vehicle control at day 1 (p = 0.0025), in line with a
higher amount of translocated materials to the lungs (Figure 1C).
At day 7, l-GO promoted significant infiltration of PMNs (p =
0.0313), similarly to MWCNTs (p = 0.0063), thus suggesting that
the typical inflammatory response to foreign materials could be
prolonged. Nevertheless, PMN infiltration to the airways was no
longer detected at 28 days after exposure, which suggested recov-
ery from the inflammatory stimulus. These results are in con-
trast with the histopathological evidence of granuloma formation
(discussed above). A possible explanation could reside in a reduc-
tion in the number of inflammatory cells that are recoverable by
lavage versus those cells that are recruited to the lungs.
To fully characterize the inflammatory response to GO sheets
in the lungs, we quantified the recruitment of immune cells to
the lung parenchyma using flow cytometry (Figure S10, Sup-
porting Information). Exposure to any of the three GO mate-
rials resulted in a general increase in CD64+CD11b+ intersti-
tial macrophages and neutrophils (Figure 4A), although only l-
GO triggered significant recruitment of interstitial macrophages
Adv. Sci. 2020, 7, 1903200 1903200 (7 of 17) © 2020 The Authors. Published by WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim
www.advancedsciencenews.com www.advancedscience.com
Figure 5. Inflammatory responses to l-GO in the lungs are characterized by the secretion of Th1 cytokines. Small portions of each individual lobe
were dissected for protein and RNA extraction. A) Heatmap showing the cytokine and chemokine expression levels of each treatment, normalized
by protein content. Each block corresponds to the median value, after normalization to the average protein expression level in the negative control
(Dextrose). Cytokine and chemokine expression levels were determined using a LEGENDplex Mouse Inflammation Panel kit, and normalized to protein
concentration determined by BCA assay. B) Individual data points corresponding to each animal are plotted alongside mean values ± SD (n = 4–5).
Statistical analysis of data acquired using the LEGENDplex assay was performed using a 2-way ANOVA test with post hoc Sidak’s multiple comparisons
test, whereas gene expression of IL-4 was analyzed using a Kruskal–Wallis test with post hoc Dunn’s multiple comparisons test. In both cases, each
treatment was only compared against the negative control: (*), p < 0.05; (**), p < 0.01. The temporal variation in the expression of IL-4 was also analyzed
using a Kruskal–Wallis test with post hoc Dunn’s multiple comparisons test: (#), p < 0.05.
(p = 0.0025), monocyte-derived dendritic cells (moDCs, p =
0.0213), and activated plasmacytoid DCs (p = 0.0163) 1 day af-
ter exposure (Figure S11, Supporting Information). Nevertheless,
immune cell recruitment was mostly resolved 7 days after instil-
lation of s-GO and us-GO, whereas l-GO seemed to promote a
prolonged infiltration of monocyte-derived CD11b+ cells (Figure
S11, Supporting Information), suggesting the establishment of a
more chronic inflammatory response to this type of GO. In con-
trast, MWCNTs were not as efficient in stimulating granuloma-
tous interstitial infiltration as l-GO (Figure 4B), despite the appar-
ent increase in interstitial macrophages (p = 0.5884). Similarly
to the cytokine expression profile (see below), mice exposed to
MWCNTs did not induce significant changes in immune cell re-
cruitment, despite a general increase at 7 days post exposure that
suggested a chronic inflammation characterized by an increased
population of eosinophils (p = 0.0901).
Cytokine expression, measured using a multiplex array, re-
vealed different pro-inflammatory responses for the different ma-
terials at 1 and 7 days after i.n. instillation (Figure 5). All three GO
materials induced only a mild acute inflammatory response, with
more pronounced effects observed at day 7 after exposure. Inter-
estingly, and in agreement with histopathological observations,
most of the measured cytokines were upregulated by exposure to
l-GO, with the most dramatic effects occurring after 7 days. This
inflammatory response was characterized by a significantly in-
creased expression of IL-1𝛼 (p = 0.0032), IL-6 (p = 0.0406), IL-23
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(p = 0.0377), IFN-𝛽 (p = 0.0398), and IFN-𝛾 (p = 0.0117), com-
pared to mice treated with 5% dextrose, 7 days after instillation
(Figure S12, Supporting Information). Exposure to s-GO did not
result in significant changes in cytokine expression, despite the
apparent increase of IL-1𝛼 (p = 0.6654) and the chemokine MCP-
1 (p = 0.3053), 1 day after administration (Figure 5). On the other
hand, us-GO elicited a mild inflammatory response, stimulating
the expression of IL-1𝛼 to similar levels to those observed in mice
exposed to l-GO, which represented a 3.1-fold increase relative to
vehicle control at day 7 post instillation (p = 0.0057). The latter
cytokine seemed to be upregulated in a size-dependent manner
at early time-points, with us-GO inducing the greatest increase
at 1 day after instillation albeit without statistical significance (p
= 0.2816). An opposite trend was found regarding the expres-
sion of IL-4, with all GO materials inducing a decreased expres-
sion at day 1 despite the non-significance compared to vehicle
control (p = 0.1244). This inhibition was followed by a signifi-
cant increase in IL-4 expression in mice exposed to s-GO (p =
0.0265), to levels similar to the vehicle control at day 28 post ex-
posure. Finally, MWCNTs did not induce statistically significant
changes in cytokine production, despite an apparent increase of
pro-inflammatory cytokines at day 7 post exposure.
2.6. Transcriptomics Analysis of Lungs Exposed to GO Sheets
To gain further molecular insight into the pulmonary responses
to the three different GO materials, we performed RNA sequenc-
ing on total RNA extracted from lung tissues at days 1, 7, and
28 post exposure. Sequencing was performed using the Illumina
HiSeq2500 platform, and sequencing reads were aligned against
the Mus musculus (GRCm38) genome. RNA sequencing gener-
ated 500 GB of raw sequence data with very high sequencing
depth (>15 million reads per sample). Differentially expressed
genes (DEGs) displaying a fold change (logFC) ≥ 0.5, and p ≤
0.05 were considered for functional (bioinformatics) analysis. En-
riched networks, molecular functions, and pathways were elabo-
rated using the Ingenuity Pathway Analysis (IPA) tool.[31] Venn
diagrams were used to group unique and common DEGs iden-
tified in mice exposed to GO materials at 1, 7, and 28 days
post exposure (Figure S13A, Supporting Information). RNA se-
quencing results displayed in this manner revealed distinct time-
dependent patterns of gene expression for all three GO mate-
rials. Markedly, gene expression changes were attenuated at 28
days post exposure for us-GO when compared to days 1 and 7, in
line with the observation that histopathological signs of inflam-
mation were largely resolved at this time-point. In contrast, for
l-GO, the number of DEGs (both up- and downregulated genes)
continued to increase up to 28 days post exposure, indicative of a
long-lasting pulmonary response to this material.
In order to compare the impact of the three different GO ma-
terials, we then performed hierarchical clustering analysis of the
top “diseases and biofunction” pathways identified by IPA at day
28 (Figure 6A). The data showed remarkable lateral dimension-
dependent differences in affected pathways. Notably, while all
three GO materials affected pathways related to inflammation or
immune cell function, several pathways annotated as “lung can-
cer related” in IPA were only affected in mice exposed to l-GO
for this time point (i.e., not found after either us-GO or s-GO
exposure). Further analysis of the latter pathways revealed genes
encoding matrix metalloproteinases (such as MMP3) and cathep-
sins (including CTSB and CTSZ), as well as the gene encoding
the protein serpin B2 (also known as plasminogen activator in-
hibitor type 2 or PAI-2). Similarly, when the top most-affected
“canonical pathways” were clustered, distinct size-dependent dif-
ferences were observed at day 28 post exposure (Figure S13B,
Supporting Information). The top “diseases and biofunction”
pathways identified by IPA at day 1, 7, and 28 for each individual
GO material are reported in Figures S14–S16, Supporting Infor-
mation. Numerous pathways related to lung inflammation were
affected, which agreed well with other experimental data reported
above.
To illustrate these findings, the genes in the “inflammation
of the lung” pathway that were found to be significantly per-
turbed by l-GO at day 28 are depicted in Figure 6B. These include
genes such as PYCARD, encoding the protein ASC (apoptosis-
associated speck-like protein containing a caspase recruitment
domain) a key adaptor of the inflammasome[32]; the gene en-
coding the IL-1 receptor antagonist; genes encoding mem-
bers of the C-type lectin/C-type lectin-like domain (CTL/CTLD)
superfamily[33]; or the gene encoding MMP12 (Matrix Metal-
lopeptidase 12, also known as macrophage metalloelastase or
macrophage elastase).[34] Notably and in agreement with the his-
tological data, none of the GO materials were found to affect fi-
brosis pathways. Finally, network analysis of DEGs performed at
day 28 post l-GO exposure revealed that both TNF-𝛼 and IFN-
ɣ acted as central nodes or putative regulators of the affected
genes, as shown in Figure 6C; Figures S14–S16, Supporting
Information.
3. Discussion
Understanding the potential hazard associated to a pulmonary
exposure to GBMs or other 2D materials is a major goal of scien-
tists, regulatory agencies, and industrial stakeholders. However,
while there are several studies on the pulmonary impact of GNPs,
very few studies have been performed to date on other GBMs
including GO,[7] and they focused primarily on acute response
with a maximum follow-up of 14–21 days post exposure.[35,36]
Herein we studied the biodistribution, biotransformation, and
pulmonary response to GO in mice for up to 90 days after sin-
gle i.n. instillation of GO sheets with varying lateral dimensions
(50 µg per animal). We demonstrated a size-dependent transloca-
tion to the lower airways. In the airways, the formation of material
agglomerates was also size-dependent: the larger the materials,
the greater the agglomeration. However, regardless of their pri-
mary lateral dimensions, all materials were submitted to clear-
ance and had undergone a time-dependent biotransformation,
which left behind materials with an altered crystalline structure.
In terms of pulmonary response, adverse outcomes were also
size-dependent; with micrometer-sized GO inducing more pro-
nounced and long-lasting effects when compared to nanometer-
sized GO. Importantly, only the material suspensions containing
micrometer-sized GO sheets triggered the formation of granulo-
mas that persisted for up to 90 days. Yet no significant pulmonary
fibrosis was observed after exposure to these large materials.
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Figure 6. RNA-seq analysis reveals size-dependent effects of GO in inflammation-related pathways. A) Hierarchical clustering analysis of the top diseases
and biofunctions pathways identified by IPA in lung tissue samples of mice exposed for 28 days to us-GO, s-GO, and l-GO. DEGs having ≥0.5 log fold
change and ≥ 0.05 FDR were included in the analysis. The color coding in the heatmap depicts the p-values for the pathways shown. B) IPA analysis was
conducted on DEGs identified at day 28 post exposure. The pathway inflammation of the lung was significantly affected in lungs of animals exposed to
l-GO. Red denotes upregulated genes, and green denotes genes that are downregulated. C) Network analysis of DEGs identified in the lungs of mice at
28 days post-exposure to l-GO. IPA suggested that IFN-𝛾 and TNF-𝛼 (highlighted in yellow) are main regulators of the affected pathways by l-GO.
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3.1. Lateral Dimensions Govern the Biodistribution and
Pulmonary Responses to GO
In comparison to s-GO or us-GO, greater amounts of l-GO
were detected in the nasal cavity and GI tract, while lower
amounts were measured in the lungs. These findings suggest
that micrometer-sized GO sheets were less able to penetrate
the lung airways than the other two materials, and more likely
to undergo mucociliary clearance from the upper airways, as
previously postulated when considering solely the nanomaterial
size.[37] However, despite the lowest dose delivered to the lower
airways, l-GO induced the strongest granulomatous inflamma-
tion (histopathology) and the highest impact at the molecular
level (whole lung RNA sequencing), hence suggesting a higher
material reactivity, in agreement with previous studies report-
ing larger materials to be more deleterious.[15,20,21,38] In addition,
granuloma formation after l-GO exposure appeared to be strongly
correlated with the formation of material agglomerates, which
were the largest amongst the three materials and persisted for
up to 90 days, as revealed by Raman imaging.
The greatest lung burden was found in s-GO exposed mice,
which in turn elicited the strongest response in the airways. In-
deed, a greater neutrophil infiltration to the airways correlated
well with a greater delivered dose; however, s-GO did not exert a
strong inflammatory cytokine secretion or molecular impact in
lungs, suggesting that the biological effects of s-GO might reside
primarily in the airways rather than the lung parenchyma. As in
l-GO exposed mice, material agglomerates persisting for up to
90 days were found in s-GO exposed animals. Comparable ma-
terial agglomerates persisting over 90 days were also reported by
Bengtson et al. after single i.t. instillation.[39] Likewise, Li et al.
have demonstrated a similar persistence of small GO sheets (10–
800 nm) for an equivalent period of time (3 months), also after
i.t. instillation.[40] In that study, GO sheets were causing acute
lung injury with dose-dependent inflammation and cytotoxicity,
followed by pulmonary fibrosis starting 1 month after exposure.
Despite having similar lateral dimensions, the s-GO sheets used
here exerted a much milder response (i.e., acute inflammation
without fibrosis), which could be explained by a 3.5 times lower
delivered dose to the lungs than in Li et al.[40]
Despite the presence of materials in the lower airways evi-
denced by Raman imaging at 1 and 7 days, us-GO was the ma-
terial that least interacted with the lung epithelium, supporting
the idea that material agglomeration and persistence were size-
dependent. Differences in lung burden between us-GO and s-GO
(or l-GO) can be first explained by the greater ability of us-GO to
translocate to extra-pulmonary organs (such as the brain, possi-
bly via the olfactory tract[37]), as measured by ICPMS. Secondly,
us-GO sheets were distributed more evenly within the lung air-
ways, rarely forming material agglomerates, as revealed by Ra-
man imaging. This pattern would favor us-GO likelihood of being
taken up by lung macrophages and drained to lymph nodes.[37]
Early material presence (i.e., day 1 and 7) could hence be due to
a slow uptake by airway macrophages, with degradation and/or
clearance from the alveolar region occurring over several months,
as suggested for other nanomaterials.[41] In fact, Raman signal in-
tensity for us-GO in lung sections was reduced with time. Overall,
the fate (i.e., biodistribution, agglomeration and clearance pro-
file) of us-GO sheets in the lungs agreed well with the observed
biological response to these materials (i.e., mild and transient in-
flammation, with full histological recovery by day 28 after expo-
sure), and highlighted us-GO as the less reactive materials of all
three, as previously suggested.[38]
Altogether, our findings strongly suggest that the primary lat-
eral dimensions of GO sheets, together with their ability to form
material agglomerates in the airways, are major determinant fac-
tors of their biodistribution and ensuing adverse effects in lungs.
3.2. Persistent Granulomatous Response Attenuated by
Transformation of GO
Granulomas form when the immune system attempts to wall
off a foreign agent that cannot be eliminated.[42] This physio-
logical process is for instance used to isolate infectious agents
such as Mycobacterium tuberculosis in the lungs of infected in-
dividuals who will not develop the disease.[43] Here, both s-GO
and l-GO induced the formation of granulomas that persisted
for up to 90 days, and this formation appeared to be correlated
with the presence of larger material agglomerates for these two
materials. Noticeably, the formation of granulomas after l-GO
exposure followed the recruitment of interstitial macrophages
and moDCs, which have been previously described in granulo-
matous response to both sterile and infectious agents,[44,45] and
are known to stimulate Th1 polarized immune responses during
granulomatous inflammation.[46] At day 7, the enhanced secre-
tion of both IL-6 and IFN-𝛾 was also an event favoring a Th1 re-
sponse to l-GO. In agreement with those findings, Ma et al. found
that large GO sheets (750–1300 nm) induced greater Th1 inflam-
mation in mouse lungs than small GO sheets (50–350 nm).[21]
Here, l-GO sheets also inhibited an anti-inflammatory Th2 im-
mune response by decreasing the expression of IL-4,[47] in agree-
ment with previous works in which GO was shown to attenuate
Th2 response in mice.[48] Overall, the modulation of the different
inflammation mediators observed here after l-GO exposure was
consistent with the sustainment of a pro-inflammatory granulo-
matous response.[45]
However, an important complication of persistent granuloma-
tous inflammation is fibrosis, which may cause permanent tissue
remodeling and damages, even after the causative agent has been
eliminated.[42] In addition, granuloma-driven fibrosis after pul-
monary exposure to carbon nanomaterials has been previously
ascribed for inducing loss of lung function and further patho-
logical sequelae, including cancer.[49,50] Here, granulomatous in-
flammation combined with marked fibrosis was only observed
in MWCNT (Mitsui-7) exposed animals, in agreement with pre-
vious reports.[44,51] Indeed, despite the persistence of lung gran-
ulomas after s-GO or l-GO exposure for up to 90 days, there was
no evidence of fibrosis at any time point. Bengtson et al. reported
similar absence of fibrosis for up to 90 days after GO intratracheal
instillation in mice, in spite of observing inflammation, acute
phase response, or BAL cell genotoxicity.[39] In contrast, Li et al.
showed that GO materials could induce lung fibrosis as early as 7
days.[40] Taken together, these different studies suggest that GO-
induced fibrosis might be GO material specific, even though dif-
ferences in the delivered dose to the lower airways in these differ-
ent studies should not be neglected. In the present study, the lack
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of pulmonary fibrosis despite the formation of granulomas could
be explained by a long-lasting Th1 polarized immune response
(combined with an inhibition of pro-fibrotic Th2 immune re-
sponse, as mentioned above), and an elevated level of interferons
(i.e., IFN-𝛽 (ELISA measured, significant at 7 days after l-GO ex-
posure) or IFN-𝛾 (revealed by analysis of RNA sequencing)), espe-
cially after l-GO exposure. Type I interferons (such as IFN-𝛽) have
indeed been associated with the development of chronic inflam-
mation in response to particulate matter by triggering the pro-
duction of chemokines that further attract inflammatory cells.[52]
Therefore, which material features and biological mechanisms
are specifically associated to the observed differences in differ-
ent GO materials ability to induce fibrosis should be investigated
further.
Besides precluding the development of fibrosis, the sustained
recruitment of inflammatory cells especially neutrophils and
macrophages, via for instance interferons, could also fulfil a
highly beneficial role in terms of GO metabolism and elimination
from the lungs. Indeed, previous studies have shown that neu-
trophils and macrophages could mediate the enzymatic degra-
dation of carbon nanomaterials in mouse lungs, and the fibrotic
response was more pronounced in enzyme-deficient mice when
compared to wild-type mice.[53,54] Taken together, these results
demonstrated that biodegradation is endogenously alleviating
the adverse effects of carbon nanomaterials, including lung fi-
brosis. In line with these data, Girish et al. provided the first evi-
dence of in vivo degradation of oxidized graphene in several mice
organs.[55] More recently, we have also demonstrated that GO can
be enzymatically degraded in a matter of hours when incubated
ex vivo with activated human neutrophils.[29] In the present study,
changes in the Raman signature of GO present in lung sections
were also suggestive of biodegradative processes. In particular,
l-GO suffered pronounced structural changes in the lungs and
displayed a gradual but advanced carbon amorphization.
Overall, the lack of fibrosis despite the persistence of granulo-
mas and material agglomerates might hence be explained by the
biotransformation of GO materials into less reactive materials,
which in turn did not appear to induce pro-fibrotic Th2 immune
response. Therefore, further investigations should focus on the
association between biotransformation of GO and Th1/Th2 po-
larized immune responses, and the role of macrophages in GO
degradation.
3.3. RNA Sequencing Provides Insights into Pathway of
Pulmonary Responses to GO
Transcriptomics approaches afford a considerable degree of sen-
sitivity and are vastly superior to traditional microarray-based
approaches.[21] Using RNA sequencing, we found distinct, size-
dependent effects at gene expression level matching the size-
dependent histopathological findings; thus confirming the abil-
ity of transcriptomics approaches to detect biologically relevant
changes.[56] In particular, there was a statistically significant up-
regulation of MMP12 in mice exposed to l-GO; this is noteworthy
as genetic variants of the gene encoding this protein have been
associated with different human lung diseases,[57] including em-
physema, commonly associated to smoking.[58] It may therefore
be of interest in future work to study this putative link to lung
diseases in the context of chronic GO exposure. Similarly, further
analysis of RNA sequencing data revealed that both TNF-𝛼 and
IFN-ɣ were central regulators for the affected genes, highlighting
the key role of inflammation mediators in the regulation of gene
expression in response to l-GO exposure.
More importantly, several pathways annotated as “cancer-
related” were affected by l-GO (especially at day 28), but not by
s-GO or us-GO, including the gene encoding serpin B2, a pro-
tein involved in both inflammation and cancer.[59] Although these
pathways were significantly perturbed, activation scores for each
individual gene were not. When putting together granulomas for-
mation and cancer-related pathways activation, both observed af-
ter l-GO exposure, it is important to consider that the multinu-
cleated macrophages present within granulomas may in fact ac-
quire epithelial cell like features. Indeed, a recent study suggested
that granuloma macrophages and pre-malignant epithelial cells
may share common mechanisms of adaptation to chronic geno-
toxic stress.[60] In tuberculosis, granuloma macrophages are also
known to adopt an epithelioid appearance, and to undergo re-
programming events involving E-cadherin-dependent formation
of epithelial-like cell-cell junctions.[43] Thus, one should be cau-
tious concluding that the present transcriptomics results point
toward a definite pro-carcinogenic potential of l-GO. In fact, it
remains possible that some of the gene expression changes ev-
idenced here are reflective of the granulomatous inflammation
or other underlining biological processes sharing commonalities
with cancer pathways such as EMT, as previously reported for re-
duced GO.[61] Therefore, more detailed analysis of the potential
carcinogenicity of micrometer-sized GO sheets is warranted. In
particular, attention should be paid to comparing the gene expres-
sion profiles in granuloma macrophages and in the whole lung
tissue.
3.4. Considerations Regarding the Exposure Model
and Its Implications
The present results highlight some values of i.n. instillation in
comparison to or alongside i.t. instillation. Although both meth-
ods provide good control of the administered doses, i.t. instilla-
tion enables a superior delivery of the nominal dose of materi-
als to the lower respiratory tract. On the other hand, i.n. instilla-
tion does not bypass the upper respiratory tract or the mucocil-
liary clearance, thus providing a more realistic assessment of the
ability of materials with varying dimensions to reach the lower
airways, and a better evaluation of their impact considering the
actual delivered dose. However, material agglomeration in the
nasal cavity upon i.n. instillation may affect the delivered dose
to the lungs due to potential retention in the cavity, as observed
here for l-GO. Conversely, the nasal cavity of mice has significant
anatomical and physiological differences compared to humans,
including a much greater surface area of the olfactory epithelium
relative to the total mucosal surface.[62]
In our view, the main limitation of the present study was, how-
ever, the delivery of a single dose administered as a bolus; even
though this dose was similar to that of several other in vivo stud-
ies of GBMs.[7] Using the allometric relationships between mice
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and humans, we estimated that the GO dose used here in mice
(50 µg) would correspond to a lung burden equivalent to a hu-
man occupational exposure lasting from 2.3 months up to ap-
proximately 23.5 years at maximum recommended levels, that
is, 50 µg m−3 (see calculations in Supporting Information). In
another study using gold standard sub-chronic inhalation expo-
sure of rats, the highest dose deposited in the lungs at aerosol
concentration of 9.78 mg m−3, was estimated to be 0.515 mg GO
(dimensions 0.5–5 µm).[36] Following the allometric relationships
between rats and mice,[70,71] we estimated that this is equivalent
to a deposited dose of 64 µg per day in the mouse lungs over
a period of 5 days (see calculations in Supporting Information).
Therefore, the single bolus dose of 50 µg used here is not exces-
sively high compared to standard inhalation studies. In order to
more adequately replicate the type of exposures observed in oc-
cupational settings and establish exposure limits for occupational
health as well as inform safety risk assessments, it would, how-
ever, be important to apply repeated administration of GO, using
inhalation or oro-pharyngeal instillation, in future work.
4. Conclusions
The present study demonstrates that lateral dimensions play a
fundamental role in the pulmonary response to GO after in-
tranasal instillation in mice. Micrometer-sized GO induced the
strongest adverse response, including granulomas persisting for
up to 90 days, despite a reduced translocation to the lungs;
whereas animals exposed to nanometer-sized GO displayed full
histological recovery by day 28. Whole tissue molecular analysis
of the lung response to the different tested materials confirmed
the very distinct and size-dependent effect of each GO. Impor-
tantly, it highlighted some common pathways between cancer de-
velopment and response to micrometer-sized GO exposure that
require further investigations. Finally, our results revealed that
regardless of their dimensions GO sheets while in the lungs
are enduring in situ biotransformation leading to a degradation
of their crystalline structure, which may partly be ascribed to
the absence of lung fibrosis despite the long-term persistence
of both granulomas and material agglomerates in the case of
micrometer-sized GO. Based on our results, it is unlikely that oc-
cupational exposure to nanometer-sized GO (s-GO and us-GO) at
realistic air concentrations would induce significant pulmonary
toxicity. Considering the growing usage of GO or other GBMs in
spray coating for anti-corrosion solutions, we believe the present
findings will be essential toward the implementation of a safer-
by-design approach in the industrial development of GBM en-
hanced products or applications, for the benefit of workers and
end-users.
5. Experimental Section
Material Preparation: GO dispersions were prepared following a mod-
ified Hummers’ method under endotoxin-free conditions, as previously
described.[22] Briefly, the difference in the production of these materials
consisted in the application of ultrasounds to break down the GO sheets,
after oxidation of graphite flakes. l-GO was not sonicated, whereas s-GO
and us-GO underwent sonication steps of 5 min and 4 h in a bath son-
icator operating at 80W (VWR, UK) before purification by centrifugation.
The morphology (AFM and TEM imaging) and surface properties (XPS
analysis) of the three GO materials tested in this study have been pre-
viously fully characterized and reported.[22] Biodistribution studies were
performed after chemical functionalization of GO sheets with NH2-PEG4-
DOTA via epoxide ring opening reaction, as previously reported.[26] Physic-
ochemical characterization of GO-DOTA sheets, including labeling stabil-
ity, demonstrated the maintenance of the oxidation degree and structural
properties, making these probes suitable for biodistribution studies. For
those studies, GO-DOTA probes were labeled after chelation of metal iso-
topes, either the natural 115In (Merck-Sigma, UK) or the radioactive 111In
(Mallinckrodt, UK), as previously described.[26] The MWCNTs (MWCNT-
7, Mitsui-7) used in this study were kindly provided by Prof Ulla Vogel
(National Research Centre for the Working Environment, Denmark, and
Technical University of Denmark).
Animal Exposures: Six to 8-week old female C57BL/6 mice (Envigo,
UK) were allowed to acclimatize for 7 days prior to any experiment. An-
imals were kept in groups of five with free access to water and food, under
a regular 12 h light/dark cycle between 7 am and 7 pm, at a temperature of
19–22 °C and relative humidity of 45–65%. All procedures were conducted
after ethical approval from the UK Home Office, under Project License no.
70/7763, in accordance with the ARRIVE guidelines for animal research.[63]
Experiments were carried out using four to five animals per group. All GO
materials were dispersed in an aqueous solution of 5% (m/v) dextrose in
ultrapure water (5% dextrose), at a concentration of 1 mg mL−1, about
30 min before administration. MWCNTs were dispersed at the same con-
centration in an aqueous solution of 0.9% (m/v) sodium chloride supple-
mented with 0.5% (m/v) bovine serum albumin (BSA), followed by bath
sonication for 10 min at 80 W (VWR, UK). Both dispersants were sterile
filtered (Merck Millipore, PES membrane, 0.2 µm, 33 mm) prior to use.
Animals were anesthesized by inhalation of 2.5% isoflurane in 100% oxy-
gen flowing at 2 L min−1. Mice in experimental groups were instilled with
50 µL of the respective nanomaterial dispersions (i.e., 50 µg per mouse),
which were equally distributed in each nostril. The same volume of 5%
dextrose solution was given to the control group. During administration,
the animals were held in a supine position, tilted to about 60°, in order to
effectively introduce the full dose. Mice were observed until full recovery,
which occurred within 5 min after instillation.
Biodistribution Studies: Mice exposed to GO-DOTA labeled with the
natural isotope 115In (for ICP-MS) were dissected 1 and 7 days after i.n. in-
stillation, and organs of interest were extracted and washed in PBS 1x to re-
move excess blood. Each sample was placed in a small glass vial and dried
under a fume hood for several days. Both wet and dry weights were mea-
sured using a microbalance (Sartorius MC210S, Goettingen, Germany)
prior to tissue solubilization. In the case of GO-DOTA labelled with ra-
dioactive 111In (for autoradiography), lungs were extracted 1 day after ad-
ministration, and only tissue-dried to remove excess liquid.
ICP-MS. Dried organs were solubilized following a protocol involving
multiple rounds of exposure to 1 mL of 30% hydrogen peroxide (Merck-
Sigma Aldrich, UK) at 140 °C until drying, followed by another step using
70% nitric acid (Merck-Sigma Aldrich, UK). At the end of the solubiliza-
tion process, each sample was reconstituted with 5 mL of 2% nitric acid.
Removal of organic matter was completed by filtering through a 0.2 µm
PES membrane (Merck Millipore, UK). Inductively-coupled plasma mass
spectrometry (ICP-MS) measurements were performed at the Manchester
Analytical Geochemistry Unit, University of Manchester, using an Agilent
7500 Series ICP-MS system (Agilent, UK).
Autoradiography. Deposition of GO-DOTA in the lungs was investi-
gated by chelating with 111In. As a vehicle control, mice were exposed
to the DOTA[111In] probe. All probes were administered with similar
radioactivity (5.5–6.5 MBq), corresponding to the same volume of in-
stilled dose. Extracted lungs were fixed to two autoradiography cas-
settes (Kodak Biomax Cassette) using transparent sticky tape, and left
in contact with super sensitive plates (Cyclone storage phosphor screen,
Packard) for 3 days. Autoradiographs were scanned using a cyclone phos-
phor detector (Packard Biosciences, UK) and processed using OptiQuant
software (version 3.1, Packard Bioscience). Signal intensity scales were
matched to take into account minor differences in background of the two
cassettes.
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Sample Collection: Mice were sacrificed at days 1, 7, 28, or 90 days
after exposure by overdose via intraperitoneal injection of 0.2 mL pento-
barbitone. Except at day 90, BAL was performed by injecting the airways
with 1.5 mL of Hank’s balanced salt solution (HBSS, Gibco, Thermo Fisher
Scientific, UK), which were slowly flushed up and down prior to extraction
to a 1.5 mL microcentrifuge tube, which was immediately placed on ice
until processing. At all considered time points, the lungs were carefully
dissected from the large airways and small portions of each lobe were
extracted for RNA extraction. Tissue samples for protein analysis were
also collected at days 1 and 7 post exposure. Tissue samples were placed
in freshly prepared RIPA buffer or RNAlater (Invitrogen, Thermo Fisher
Scientific, UK), respectively, and placed immediately on ice. Samples in
RNAlater solution were incubated overnight at 4 °C prior to storage at
−20 °C, until further processing. The remaining lung tissue was fixed in 4%
paraformaldehyde (PFA) overnight at 4 °C. The left lung was transferred to
a solution of 70% ethanol before paraffin embedding for histology, while
the right lung was cryopreserved in 30% (m/v) sucrose dissolved in ul-
trapure water before snap-freezing in optical cutting temperature (OCT)
medium for cryo-sectioning.
Histopathology: Paraffin-embedded lung samples were sectioned us-
ing a Leica RM2255 microtome set at a thickness of 5 µm. Hematoxylin
and eosin or Masson’s trichrome staining was employed to measure
pathological changes and collagen deposition, respectively. Images were
collected using a Pannoramic 250 Flash slide scanner (3D Histech, Hun-
gary), in bright-field mode, and analyzed using Pannoramic Viewer (ver-
sion 1.15.4, 3D Histech, Hungary). Areas of evident interstitial infiltration,
characterized by alveolar wall thickening and granuloma formation, were
manually segmented using ImageJ software (version 1.51, National Insti-
tutes of Health, Bethesda, MD). Cell infiltration was defined as the sum
of these manually segmented areas divided by the total area of the lung
section. Infiltrate size corresponded to the area of each segmented area.
Raman Mapping: Lung samples snap-frozen in OCT were sectioned
using a Leica CM3050S cryotome set at a thickness of 20 µm. Cryo-sections
of lungs exposed to GO materials were gently rinsed with PBS 1x, ultrapure
water, and 100% methanol, in order to remove any excess of OCT com-
pound and salts, and to post-fix the section. Once dried, lung sections
were imaged under an Olympus BX41 microscope, part of the DXRxi Ra-
man system (Thermo Scientific, UK), using a 50x objective. Raman spectra
were acquired using a laser of 𝜆 = 633 nm operating at 0.4 mW, through
a 50 µm pinhole aperture with an exposure time of 0.125 s. Raman corre-
lation maps were plotted using the OMNICxi software (Thermo Scientific,
UK), in order to reflect the spatial distribution and transformation of GO in
the lungs. An arbitrary color scale was defined at each pixel to describe the
similarity between the acquired Raman spectrum at that coordinate and
a reference spectrum of GO, focusing on a region comprising both the D
and G bands (1145–1810 cm−1). Black color represents background sig-
nal, whereas white color represents the highest similarity to the reference
spectrum, indicating the presence of GO. Red color represents a weaker
signal of the D and G bands compared to the reference spectrum.
BAL Analysis: BAL fluid samples were centrifuged at 1500 rpm (214 g)
for 5 min at 4 °C using a Hettich Universal 320R centrifuge (Hettich Zen-
trifuger, Germany). Supernatant was collected for the quantification of to-
tal protein and amount of released lactate dehydrogenase (LDH), whereas
the pellet was re-suspended in 0.5 mL of PBS for differential cell counting.
BCA Assay. Protein release in BAL fluid was quantified using the bicin-
choninic acid (BCA) protein assay (Pierce, Thermo Fisher Scientific, UK),
according to the manufacturer’s instructions. Briefly, 200 µL of BCA
reagent mixture were added to 25 µL of each sample, and incubated at
37 °C for 30 min in a 96-well plate (Corning, UK). Optical absorbance
at 562 nm was measured using a FLUOstar Omega plate reader (BMG
Labtech, UK). The protein concentration of each sample was determined
via extrapolation from the BSA standard curve, defined with albumin stan-
dards (0–2000 µg mL−1). Standard solutions and BCA reagent mixture
were freshly prepared before each assay.
LDH Assay. LDH content was measured using the CytoTox 96 Non-
Radioactive Cytotoxicity Assay (Promega, UK). In this case, 50 µL
of each sample were mixed with 50 µL of LDH substrate mix, fol-
lowed by incubation in the dark for 15 min at room temperature.
After adding 50 µL of stop solution, optical absorbance at 490 nm
was measured using a FLUOstar Omega plate reader (BMG Labtech,
UK).
Differential Cell Counting. Cells in BAL fluid were quantified using a
haemocytometer after Trypan Blue exclusion staining. Live cells that did
not internalize the dye were visualized under a PrimoVert inverted micro-
scope (Carl Zeiss, UK) using a 20x objective. Cell suspensions underwent
a cyto-centrifugation step at 600 rpm (34 g) for 5 min at 4 °C, followed
by fixation in ice-cold 100% methanol for 10 min. Differential cell staining
was performed using the Kwik-Diff kit (Thermo Fisher Scientific, Shandon,
UK) according to the manufacturer’s protocol. Stained cells were imaged
under an Olympus BX41 microscope (Olympus, UK).
Flow Cytometry: In a separate experiment, mice were intranasally in-
stilled with carbon nanomaterials and sacrificed 1 and 7 days post ex-
posure. Lungs were carefully dissected from the large airways and split
into small portions using scissors. These lung portions were transferred
to tubes containing 2 mL of digestion buffer, comprised by Liberase-TM
(Roche, UK) at a concentration of 0.4 Wünsch units mL−1 and DNase I
(Roche, UK) at a concentration of 0.01 mg mL−1, in RPMI-1640 cell cul-
ture medium (Life Technologies, Thermo Fisher Scientific, UK), supple-
mented with 10% fetal bovine serum (FBS, Gibco, Thermo Fisher Sci-
entific, UK). After shaking for 30 min at 37 °C, the digested lungs were
filtered through a 100 µm mesh filter and supplemented with cell cul-
ture medium with 5 mm EDTA. The resulting cell suspension underwent
lysis of red blood cells using Red Blood Cell Lysing Buffer Hybri-Max
(Merck-Sigma Aldrich, UK) before centrifugation at 500 g for 7 min to
remove cell debris. Obtained cell suspensions were quantified by Trypan
blue exclusion before staining for flow cytometry. The staining protocol
involved the incubation with the Live/Dead UV viability dye (Life Tech-
nologies, Thermo Fisher Scientific, UK) for 20 min at room temperature,
before washing and staining with a mixture of Fc blocking agent (anti-
mouse CD16/CD32) and fluorochrome-conjugated antibodies (see Table
S4, Supporting Information) for 30 min at 4 °C. Cells were finally fixed
with 2% PFA in cell culture medium for 20 min at room temperature, and
washed prior to flow cytometry measurements. Data were acquired us-
ing a BD Fortessa flow cytometer (BD Biosciences, UK), and then pro-
cessed using FlowJo (version 10, FlowJo, LLC, USA). Appropriate single-
color and fluorescence minus one (FMO) controls were performed for all
fluorochromes, in order to compensate any spectral overlap and poten-
tial non-specific binding and/or fluorescence emission in undesired chan-
nels. Cell populations were defined as shown in Figure S10, Supporting
Information. Cell events were gated after excluding cell debris and dou-
blets, using both forward (FSC) and side scatter (SSC). Leukocytes were
defined by selecting CD45+ cells that had low fluorescence intensity for
the Live/Dead signal. Neutrophils were discriminated based on their high
expression of Ly6G and CD11b, and confirmed by their intermediate SSC
values, indicating their granularity. The remaining cells were gated based
on their expression of Siglec-F. Siglec-F+ cells were distinguished based on
their expression of CD11b, with eosinophils expressing CD11b and hav-
ing high SSC. Alveolar macrophages, on the other hand, were CD11b−
and confirmed to be CD11c+ and CD64+. Myeloid cells were further gated
based on their expression of CD11b and CD11c. Dendritic cells (DCs) were
considered CD11c+ cells, and based on their expression of CD11b, Ly6C
and MHC-II they could be further classified: i) conventional DCs (cDCs)
were considered CD11b− CD11c+ Ly6C− MHC-II+; ii) plasmacytoid cells
(pDCs) could be found in the CD11b− CD11c+ Ly6C+ MHC-II−/int pop-
ulation; iii) CD11b+ DCs differed from cDCs due to their expression of
CD11b (CD11b+ CD11c+ Ly6C− MHC-II+); and iv) monocyte-derived DCs
(moDCs) were CD11b+ CD11c+ Ly6C+ MHC-II−/int. Monocytic cells were
gated on the CD11b+ CD11c− population, with interstitial macrophages
expressing CD64. Monocytes were divided into classical (Ly6C+) or pa-
trolling (Ly6C−), depending on their activation state. Lymphocytes were
identified as CD3+, from the population of CD11b− CD11c− cells, and fur-
ther classified either as CD4+ or CD8+ T cells. The obtained percentages
for each cell population were multiplied by the number of live cells after
Trypan blue exclusion, rendering absolute cell counts.
Cytokine Analysis: Tissue incubated in RIPA buffer was homogenized
with 5 mm stainless steel beads using a TissueLyser LT system (QIAGEN,
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UK) operating at 50 Hz for 5 min, followed by centrifugation at 2600 g
for 5 min to remove cell debris. The obtained supernatant was utilized
in subsequent protein analysis. Protein concentration was determined us-
ing the BCA assay, as described above. Quantification of a set of inflam-
matory cytokines and chemokines (IL-1𝛼, IL-1𝛽, IL-6, IL-10, IL-12p70, IL-
17A, IL-23, IL-27, MCP-1, IFN-𝛽, IFN-𝛾 , TNF-𝛼, and GM-CSF) was carried
out using a LEGENDplex Mouse Inflammation kit (BioLegend, UK) ac-
cording to the manufacturer’s recommendations. Fluorescence intensi-
ties of the multiple analytes were recorded using a BD FACSCanto flow
cytometer (BD Biosciences, UK). Data analysis was performed with spe-
cialized software provided by the manufacturer of the assay Cytokine con-
centration was normalized by total protein concentration as determined
above.
RNA Extraction and RT-qPCR: Tissue samples in RNAlater solution
(Invitrogen, Thermo Fisher Scientific, UK) were homogenized using a Tis-
sueLyser LT (QIAGEN, UK) as described above. Homogenized samples
were then loaded onto spin cartridges containing silica membranes, for
extraction of total RNA performed using a PureLink RNA Mini kit (Invit-
rogen, Thermo Fisher Scientific, UK) according to the manufacturer’s in-
structions. Total RNA concentration and purity were calculated by mea-
suring the optical density at 230, 260, and 280 nm, using a Biophotome-
ter Plus spectrophotometer (Eppendorf AG, Germany). For quality con-
trol purposes, RNA samples were required to have absorbance ratios at
260 nm/280 nm and 260 nm/230 nm above 1.8. First-strand cDNA was
created from 1 µg of RNA in a total volume of 20 µL using the High Capac-
ity cDNA Reverse Transcription kit (Invitrogen, Thermo Fisher Scientific,
UK). The cDNA synthesis reaction followed a protocol of 10 min at 25 °C,
followed by 2 h at 37 °C, and 5 min at 85 °C, executed by a CFX96 real-
time PCR system (BioRad, UK). Quantitative PCR was performed using
the CFX96 real-time PCR detection system (BioRad, UK). Each sample con-
sisted of 2 µL of cDNA obtained from reverse transcription, each primer at
500 nm, and 10 µL of PowerUp SYBR Green Master Mix (Applied Biosys-
tems, Thermo Fisher Scientific, UK) in a 20 µL reaction. Primers are listed
in Table S5, Supporting Information. PCR protocol consisted of an initial
activation step at 50 °C for 2 min, followed by a denaturation step at 95 °C
for 2 min, prior to 40 cycles of amplification (denaturation at 95 °C for 15 s,
then annealing and elongation at 60 °C for 1 min). Melting curves between
65 and 95 °C were also obtained, in order to confirm amplification speci-
ficity and the absence of artefacts such as primer dimers. No-template
controls did not return any Ct values. Each sample was analyzed in du-
plicate, and the mean Ct value was used for further calculations. Relative
changes of gene expression of each treatment were calculated according
to the Livak method as 2−ΔΔCt, where the obtained ΔCt values are sub-
tracted by those obtained with the negative control (Dextrose). The ΔCt
values were calculated by subtracting the Ct value of each individual gene
by the Ct value of the housekeeping gene in each sample, in order to nor-
malize the amount of each transcript.
RNA Sequencing: Total RNA from tissue sample was extracted as de-
scribed above. RNA quantity and RNA integrity number (RIN) were as-
sessed by Agilent 2200 bioanalyzer. Sample RNA with RIN values below 8
was discarded. The isolated RNA samples were stored at −80 °C until RNA
sequencing was carried out. Illumina TruSeq Stranded mRNA Library Prep
Kit (Illumina, Inc., San Diego, CA) was used to prepare mRNA sequenc-
ing libraries. Briefly, 1000 ng of total RNA was used for mRNA isolation
using poly dT-coated beads. After purification, the mRNA was chemically
fragmented into small pieces, which was subsequently used as a template
for cDNA synthesis using reverse transcriptase followed by short frag-
ment removal from another purification step. After end-repair, adapter lig-
ation, and index codes adding for each sample, PCR amplification was con-
ducted. Unaligned adapters were removed twice after adapter ligation and
PCR amplification. The quality of the libraries were examined by Caliper
LabChip GX/HT DNA high sensitivity and the quantitation of libraries
were measured by Qubit dsDNA HS. All 36 libraries were paired-end se-
quenced on a HiSeq2500 (HiSeq Control Software 2.2.58/RTA 1.18.64)
with a 2 × 126 setup using “HiSeq SBS Kit v4” chemistry. The conver-
sion from Bcl to FastQ was performed using “bcl2fastq2 v2.19” from the
CASAVA software suite. The quality scale used is Sanger/phred33/Illumina
1.8+.
Bioinformatics Analysis: The quality check involving the analysis of
sequence quality, GC content, the presence of adaptors, overrepre-
sented sequences, duplication level in order to detect sequencing er-
rors, PCR artifacts or adapter contaminations was conducted using soft-
ware tools FastQC. Fastq-Screen was performed to check the composi-
tion of the libraries. The mRNA sequencing data were analyzed using the
rnaseq pipeline (https://github.com/nf -core/rnaseq). The preprocessed
sequencing reads were aligned against the Mus musculus (GRCm38) refer-
ence genome using STAR.[64] Subsequently, the read-counts to genes were
generated using the software featureCounts.[65] Full-length transcripts
representing multiple splice variants for each gene locus were assem-
bled and quantitated using StringTie.[66] Extensive quality-control on the
results was performed using RSeQC,[67] dupRadar,[68] and Preseq (http:
//smithlabresearch.org/software/preseq/) which generated RNA quality
control metrics, technical/biological read duplication level, and library
complexity estimation. Differentially expressed genes between different
treatments of samples were determined using edgeR.[69] Differential gene
expression levels between the healthy control lung tissue sample and the
three different GOs (us-GO, s-GO, l-GO) were estimated with a t-test. p
values were corrected with the Benjamini–Hochberg algorithm (false dis-
covery rate; FDR). DEGs having a fold change (logFC) ≥ 0.5, p-value ≤ 0.05
were considered for functional analysis. Ingenuity Pathway Analysis (appli-
cation version 220 217, content version 16 542 223) (licensed by Ingenuity
Systems, Redwood City, CA) was employed to study biological processes,
canonical pathways, upstream transcriptional regulators, and gene net-
works, based on the DEGs.
Statistical Analysis: All experiments were analyzed using GraphPad
Prism software (version 6.01, GraphPad Inc., USA). Data were ana-
lyzed using analysis of variance (two-way ANOVA) with post hoc Sidak’s
multiple comparisons test or Kruskal–Wallis test with post hoc Dunn’s
multiple comparisons test. In both cases, p < 0.05 was considered
significant.
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